🇺🇸 FDA
Patent

US 8741306

Kidney specific tumor vaccine directed against kidney tumor antigen G-250

granted A61KA61K2039/53A61K2039/54

Quick answer

US patent 8741306 (Kidney specific tumor vaccine directed against kidney tumor antigen G-250) held by The Regents of the University of California expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/53, A61K2039/54, A61K2039/55516, A61K2039/55522